GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Vietnam Approves SpaceX Starlink Satellite Internet Service Amid U.S. Trade Talks 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Bain Capital Secures RBI Approval to Acquire Up to 41.7% Stake in Manappuram Finance 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Grok AI Market Share Surges as xAI Faces Scrutiny Over Image Generation Controversy 
Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
Senators Urge CFIUS Review of UAE Investment in Trump-Linked Crypto Firm World Liberty Financial 
EAST RUTHERFORD, N.J., April 19, 2018 -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced a commitment to provide its stockholders with additional information regarding its environmental, social and governance (ESG) practices. Cambrex’s commitment to the environment, health and safety underpins our activities across our sites. Over approximately the next 18 to 24 months, Cambrex will develop additional disclosures relating to our ESG related policies, strategies and performance. Once available, stockholders will be able to review these disclosures on Cambrex’s website at www.cambrex.com. In connection with today’s announcement, Trillium Asset Management, LLC informed Cambrex that it has withdrawn its shareholder proposal requesting the production of an ESG report from the agenda for the upcoming 2018 Annual Meeting of Stockholders. Cambrex has appreciated Trillium’s perspective on ESG matters and the feedback we received from our investors as part of our shareholder outreach effort.
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and continuous processing. For more information, please visit www.cambrex.com.
Contact:
Tom Vadaketh
Executive VP & CFO
Tel: +201 804 3033
Email: [email protected]
